Home LiteratureArticle Details

PMID: 21067385 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't Review

Triple-negative breast cancer.

The New England journal of medicine ·Vol. 363 ·No. 20 ·2010-11-11 ·Pages 1938-48

Foulkes WD, Smith IE, Reis-Filho JS

Abstract

Triple-negative breast cancer, so called because it lacks expression of the estrogen receptor, progesterone receptor, and HER2, is often, but not always, a basal-like breast cancer. This review focuses on its origin, molecular and clinical characteristics, and treatment.

MeSH Terms

Antineoplastic Agents/therapeutic use Breast Neoplasms/drug therapy,immunology,mortality,pathology Female Genes, BRCA1 Humans Mutation Prognosis Receptor, ErbB-2 Receptors, Estrogen Receptors, Progesterone Survival Rate

Chemicals

Antineoplastic Agents Receptors, Estrogen Receptors, Progesterone Receptor, ErbB-2

Authors & Affiliations

3 authors, click to expand affiliations / ORCID

Foulkes William D

Departmentof Oncology and Human Genetics, Research Institute of the McGill University Health Centre, and the Lady Davis Institute of the Jewish General Hospital, McGill University, Montreal, QC H2W 1S6, Canada. [email protected]

Smith Ian E

Reis-Filho Jorge S

Article Info

Journal

The New England journal of medicine

Abbr.

N Engl J Med

ISSN

1533-4406

DOI

10.1056/NEJMra1001389

[email protected]

Published

2010-11-11

Pages

1938-48

Language

English

Region

United States

NLM ID

0255562

Subset

External Links

PubMed source DOI: 10.1056/NEJMra1001389 View journal details

Analysis Services

Triple-negative breast cancer.

Contact

WeChat Official Account